NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free SMMT Stock Alerts $3.88 +0.39 (+11.17%) (As of 12:51 PM ET) Add Compare Share Share Today's Range$3.48▼$3.9350-Day Range$3.28▼$5.0752-Week Range$1.30▼$5.22Volume735,663 shsAverage Volume2.19 million shsMarket Capitalization$2.72 billionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Summit Therapeutics alerts: Email Address Summit Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside129.2% Upside$8.00 Price TargetShort InterestBearish26.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$487,500 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.24) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.88 out of 5 starsMedical Sector591st out of 910 stocksPharmaceutical Preparations Industry267th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingSummit Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSummit Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted26.25% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Summit Therapeutics has recently increased by 28.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMMT. Previous Next 2.8 News and Social Media Coverage News SentimentSummit Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Summit Therapeutics this week, compared to 1 article on an average week.Search Interest14 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $487,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders83.70% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.61% of the stock of Summit Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.24) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 31.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Summit Therapeutics Stock (NASDAQ:SMMT)Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Read More SMMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMMT Stock News HeadlinesMarch 29, 2024 | insidertrades.comInsider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of StockApril 23, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Stock Crosses Below Fifty Day Moving Average of $4.14April 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 15, 2024 | americanbankingnews.comShort Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Rises By 28.6%April 14, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Trading Down 6.7%April 11, 2024 | finance.yahoo.comSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsApril 11, 2024 | businesswire.comSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsApril 10, 2024 | businesswire.comSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumApril 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 9, 2024 | reuters.comIllumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successorApril 9, 2024 | prnewswire.comIllumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development OfficerMarch 29, 2024 | investing.comSummit Therapeutics CEO acquires shares worth over $411kMarch 29, 2024 | fool.comWhy Summit Therapeutics Stock Crushed the Market This WeekMarch 14, 2024 | businesswire.comIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024March 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTMarch 5, 2024 | businesswire.comSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTFebruary 27, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) InvestorsFebruary 26, 2024 | businesswire.comSummit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 21, 2024 | uk.finance.yahoo.comSummit Therapeutics plc (SMMT)February 21, 2024 | finance.yahoo.comQ4 2023 Summit Therapeutics Inc Earnings CallFebruary 21, 2024 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call TranscriptFebruary 20, 2024 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023February 20, 2024 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ...February 20, 2024 | businesswire.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023February 17, 2024 | finance.yahoo.comSMMT Mar 2024 4.000 putFebruary 17, 2024 | finance.yahoo.comSMMT Apr 2024 3.000 callSee More Headlines Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SMMT CUSIPN/A CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees105Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+129.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.45% Return on Assets-41.17% Debt Debt-to-Equity Ratio1.29 Current Ratio9.30 Quick Ratio9.30 Sales & Book Value Annual Sales$700,000.00 Price / Sales3,498.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book31.73Miscellaneous Outstanding Shares701,700,000Free Float114,378,000Market Cap$2.45 billion OptionableOptionable Beta-1.21 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Co-CEO & Executive Chairman Dr. Mahkam Zanganeh D.D.S. (Age 54)M.B.A., Co-CEO, President & Director Comp: $657.81kMr. Ankur Dhingra (Age 47)Chief Financial Officer Comp: $530kMr. Manmeet Singh Soni (Age 46)COO & Director Comp: $591.5kProf. Dame Kay Davies DBE (Age 73)FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Abby Guzman MurphyHead of Human ResourcesMs. Divya Chari (Age 56)Head of Global Clinical Operations Mr. Dave GancarzChief Business & Strategy Officer?Mr. Will BlackHead of Information Technology?Dr. Betty Y. Chang Ph.D.Head of Research, Oncology & Inflammation?More ExecutivesKey CompetitorsEvotecNASDAQ:EVOCorcept TherapeuticsNASDAQ:CORTMerusNASDAQ:MRUSJanux TherapeuticsNASDAQ:JANXVera TherapeuticsNASDAQ:VERAView All CompetitorsInsiders & InstitutionsWealth Management Partners LLCBought 29,000 shares on 4/12/2024Ownership: 0.006%Ankur DhingraBought 100,000 shares on 3/26/2024Total: $375,000.00 ($3.75/share)Mahkam ZanganehBought 30,000 shares on 3/26/2024Total: $112,500.00 ($3.75/share)Sectoral Asset Management Inc.Bought 10,000 shares on 2/14/2024Ownership: 0.004%Aristides Capital LLCBought 80,601 shares on 2/13/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions SMMT Stock Analysis - Frequently Asked Questions Should I buy or sell Summit Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SMMT shares. View SMMT analyst ratings or view top-rated stocks. What is Summit Therapeutics' stock price target for 2024? 1 equities research analysts have issued 1-year price objectives for Summit Therapeutics' stock. Their SMMT share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 129.2% from the stock's current price. View analysts price targets for SMMT or view top-rated stocks among Wall Street analysts. How have SMMT shares performed in 2024? Summit Therapeutics' stock was trading at $2.61 at the beginning of the year. Since then, SMMT shares have increased by 33.7% and is now trading at $3.49. View the best growth stocks for 2024 here. Are investors shorting Summit Therapeutics? Summit Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 21,810,000 shares, an increase of 28.6% from the March 15th total of 16,960,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the days-to-cover ratio is presently 9.3 days. Currently, 26.3% of the company's stock are short sold. View Summit Therapeutics' Short Interest. When is Summit Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SMMT earnings forecast. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) posted its earnings results on Tuesday, February, 20th. The company reported ($0.05) EPS for the quarter. The company had revenue of $0.20 million for the quarter. What ETFs hold Summit Therapeutics' stock? ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP). When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Summit Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Wealth Management Partners LLC (0.01%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SMMT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
